Literature DB >> 24309754

Factors associated with late initiation of highly active antiretroviral therapy among young HIV-positive men and women aged 18 to 29 years in Canada.

Alexis K Palmer1, Angela Cescon, Keith Chan, Curtis Cooper, Janet M Raboud, Caroline L Miller, Ann N Burchell, Marina B Klein, Nima Machouf, Julio S G Montaner, Chris Tsoukas, Robert S Hogg, Mona R Loutfy.   

Abstract

Initiating highly active antiretroviral therapy (HAART) with low CD4 counts or AIDS-defining illnesses (ADIs) increases risk of treatment failure and death. We examined factors associated with late initiation among 18- to 29-year-olds within the Canadian Observational Cohort (CANOC) collaboration, a multi-site study of HIV-positive persons who initiated HAART after 2000. Late initiation was defined as beginning HAART with a CD4 count <200 cells/mm(3) and/or having a baseline ADI. Multivariable logistic regression was used to identify independent correlates of late initiation. In total, 1026 individuals (422 from British Columbia, 400 from Ontario, and 204 from Quebec) met our age criteria. At HAART initiation, median age was 27 years (interquartile range, 24, 28 years). A total of 412 individuals (40%) identified as late initiators. Late initiation was associated with female gender, age >25 years at initiation, initiating treatment in earlier years, and having higher baseline viral load. The high number of young adults in our cohort starting HAART late indicates important target populations for specialized services, increased testing, and linkages to care.

Entities:  

Keywords:  Canada; HIV; antiretroviral therapy; late initiation; young adult

Mesh:

Substances:

Year:  2013        PMID: 24309754     DOI: 10.1177/2325957413510606

Source DB:  PubMed          Journal:  J Int Assoc Provid AIDS Care        ISSN: 2325-9574


  3 in total

1.  Rates and correlates of antiretroviral therapy use and virologic suppression among perinatally and behaviorally HIV-infected youth linked to care in the United States.

Authors:  Shoshana Y Kahana; Maria Isabel Fernandez; Patrick A Wilson; Jose A Bauermeister; Sonia Lee; Craig M Wilson; Lisa B Hightow-Weidman
Journal:  J Acquir Immune Defic Syndr       Date:  2015-02-01       Impact factor: 3.731

2.  Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care.

Authors:  Angela Cescon; Sophie Patterson; Colin Davey; Erin Ding; Janet M Raboud; Keith Chan; Mona R Loutfy; Curtis Cooper; Ann N Burchell; Alexis K Palmer; Christos Tsoukas; Nima Machouf; Marina B Klein; Sean B Rourke; Anita Rachlis; Robert S Hogg; Julio S G Montaner
Journal:  J Int AIDS Soc       Date:  2015-10-05       Impact factor: 5.396

Review 3.  The impact of criminalization of HIV non-disclosure on the healthcare engagement of women living with HIV in Canada: a comprehensive review of the evidence.

Authors:  Sophie E Patterson; M-J Milloy; Gina Ogilvie; Saara Greene; Valerie Nicholson; Micheal Vonn; Robert Hogg; Angela Kaida
Journal:  J Int AIDS Soc       Date:  2015-12-22       Impact factor: 5.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.